An aryl hydrocarbon receptor induces VEGF expression through ATF4 under glucose deprivation in HepG2 by Jun Terashima et al.
Terashima et al. BMC Molecular Biology 2013, 14:27
http://www.biomedcentral.com/1471-2199/14/27RESEARCH ARTICLE Open AccessAn aryl hydrocarbon receptor induces VEGF
expression through ATF4 under glucose
deprivation in HepG2
Jun Terashima1*, Chie Tachikawa1,2, Kenzo Kudo2, Wataru Habano1 and Shogo Ozawa1Abstract
Background: Aryl hydrocarbon receptor (AhR) not only regulates drug-metabolizing enzyme expression but also
regulates cancer malignancy. The steps to the development of malignancy include angiogenesis that is induced by
tumor microenvironments, hypoxia, and nutrient deprivation. Vascular endothelial growth factor (VEGF) plays a
central role in the angiogenesis of cancer cells, and it is induced by activating transcription factor 4 (ATF4).
Results: Recently, we identified that glucose deprivation induces AhR translocation into the nucleus and increases
CYP1A1 and 1A2 expression in HepG2 cells. Here, we report that the AhR pathway induces VEGF expression in
human hepatoblastoma HepG2 cells under glucose deprivation, which involves ATF4. ATF4 knockdown suppressed
VEGF expression under glucose deprivation. Moreover, AhR knockdown suppressed VEGF and ATF4 expression
under glucose deprivation at genetic and protein levels.
Conclusions: The AhR-VEGF pathway through ATF4 is a novel pathway in glucose-deprived liver cancer cells that is
related to the microenvironment within a cancer tissue affecting liver cancer malignancy.
Keywords: Aryl hydrocarbon receptor (AhR), Vascular endothelial growth factor (VEGF), Angiogenesis, Activating
transcription factor 4 (ATF4), Human hepatocellular liver carcinoma cellBackground
The aryl hydrocarbon receptor (AhR) is a well-known
transcription factor that is involved in the detoxification
response to pollutants and intrinsic biological processes
of multicellular organisms. AhR forms a complex with AhR
nuclear translocator (ARNT) and regulates the expression
of drug-metabolizing enzymes.
AhR has been shown to be activated by xenobiotics
including benzo[a]pyrene and 2,3,7,8-tetrachlorodibenzo-
p-dioxin, and it induces the expression of genes contain-
ing an XRE domain in their promoter region [1,2]. The
genes, which are activated by AhR, include loci encoding
the cytochrome P450 family, which is responsible for
the phase I detoxification response, enzymes metabol-
izing endobiotics and xenobiotics, and other molecules
that function in cell differentiation [3-7]. In addition,* Correspondence: jterashi@iwate-med.ac.jp
1Department of Pharmacodynamics and Molecular Genetics, School of
Pharmacy, Iwate Medical University, 2-1-1 Nishitokuda, Yahaba-CHO, Siwa-Gun
028-3694, Iwate, Japan
Full list of author information is available at the end of the article
© 2013 Terashima et al.; licensee BioMed Cen
Commons Attribution License (http://creativec
reproduction in any medium, provided the orAhR is one of the stress response molecules in mouse
hepa1c1c7 cells; crosstalk between AhR and nuclear
factor erythroid-derived 2-related factor 2 (Nrf2) mediates
the oxidative stress response through NAD(P)H dehydro-
genase quinone 1 (NQO1) [8]. Miao et al. demonstrated
that Nrf2 transcription is directly modulated by an activated
AhR [9]. AhR has been studied not only as a mediator
of chemical toxicity but also as a regulator of vascular
development or angiogenesis [10]. Vascular endothelial
growth factor (VEGF) is a potent angiogenic factor that
plays a central role in angiogenesis, and it is a recognized
gene marker for angiogenesis [11]. VEGF expression
is induced by various environmental stresses, nutrient
deprivation [12], and hypoxia [13]. Glucose deprivation,
one of the nutrient deprivations of MCF-7/ADR cells,
induces the expression of cellular homologs of oncogenes
and angiogenic factors [14,15]. These results support the
hypothesis that glycolytic metabolism is associated with
cancer malignancy [16]. In human hepatoblastoma HepG2
cells, glucose deprivation induces VEGF expression [17].
We reported that the nuclear localization of AhR wastral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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AhR localization induced not only cytochrome P450 family
1 member A1 (CYP1A1) and 1A2 expression but also
Nrf2 expression. In addition, AhR mediates TCDD in-
duced VEGF expression [19] and relates to angiogen-
esis in mouse [20]. In this study, we report a novel
pathway that induces VEGF expression in HepG2 cells
in response to glucose deprivation. The response to
glucose deprivation that is mediated by AhR induces
VEGF expression through activating transcription factor 4
(ATF4) expression in HepG2 cells.
Results
Glucose deprivation induces VEGF expression through
AhR in HepG2 cells
In the HepG2 human liver carcinoma cell line, glucose
deprivation, or hypoglycemia, enhances VEGF mRNA ex-
pression [17]. When the medium was exchanged from high
glucose medium (4.5 g/L D-glucose) to no glucose medium
(0 g/L), VEGF mRNA expression was increased in HepG2
cells at 12 and 24 h after the medium exchange (Figure 1A).
Correspondingly, the expression level of protein was
increased under glucose deprivation at 12 and 24 h after
the medium exchange and secreted VEGF was increased
under glucose deprivation at 24 h after medium exchange
(Figure 1B and C).
VEGF is a potent angiogenic factor that plays a central
role in angiogenesis [11], and angiogenesis is a significant
step in the pre-malignancy and malignancy of cancer [21].
We expected that AhR was related to the process of cancer
cell malignancy. Tryptophan-2,3-dioxygenase (TDO)-
derived kynurenine promotes tumor cell survival through
AhR with the progression of cell malignancy [22]. AhR
is translocated to the nucleus by low glucose conditions
in HepG2 cells. AhR that is translocated to the nucleus
activates CYP1A1, 1A2, 1B1, and Nrf2 expression in HepG2
cells in low glucose conditions [18]. We expected that
the nucleus-translocated AhR was related to VEGF ex-
pression that was induced by glucose deprivation. When
AhR expression was knocked down by RNAi, VEGF
expression did not change in normal glucose condi-
tions (D-glucose = 4.5 g/L). Under glucose deprivation
(D-glucose = 0 g/L), VEGF expression was suppressed by
RNAi against AhR (Figure 1D). The expression and secre-
tion of VEGF protein were clearly suppressed by RNAi
against AhR under glucose deprivation (Figure 1E and F).
AhR and VEGF pathway analysis in silico
Figure 1D, E and F show that AhR is required for increased
expression of VEGF in HepG2 cells in glucose deprived-
conditions. However, there are no AhR binding regions on
the transcriptional regulatory domain of VEGF. Therefore,
we expected that AhR did not regulate VEGF expression
directly. We tried to extract candidate VEGF transcriptionalregulators that could be induced by glucose deprivation
through in silico analyses using Ingenuity Pathway Analysis
(IPA). We extracted the molecules that were classified
as “regulation of expression” and could possibly regulate
VEGF expression directly (Figure 2A). Moreover, the
candidate molecules of interest were those molecules that
could be integrated into the pathway where AhR was a
starting molecule and VEGF was at the end of the pathway.
As a result, ATF4, estrogen receptor 1 (ESR1), and endo-
thelial PAS domain protein 1 (EPAS1) were integrated into
the AhR to VEGF pathway (Figure 2B). In low glucose
conditions, AhR induced Nrf2 expression [18]. Similarly,
in no glucose conditions, AhR induced Nrf2 expression
(data not shown). In nuclei, phosphorylated Nrf2 protein
induced the expression of ATF4 protein [23] and bound
to ATF4 protein [24,25]. We expected that ATF4 has the
high possibility for interacting with AhR through Nrf2 and
inducing VEGF expression. Therefore, we focused on the
ATF4 interaction with Nrf2.
AhR regulates ATF 4 expression under glucose
deprivation in HepG2 cells
The ATF4 transcript level was higher after 12 and 24 h
of culture in glucose-deprived conditions than in high-
glucose conditions (Figure 3A). The protein levels differed
between glucose deprivation and high glucose after 24 h
of cell culture, but they did not differ much after 12 h of
culture (Figure 3B). There are no reports that AhR regulates
ATF4 expression directly. According to our current in
silico analysis, AhR possibly regulates ATF4 expression
through Nrf2, FOS, CCAAT enhancer-binding protein
alpha (CEBPA), MAF, and p53. In HepG2 cells, AhR knock-
down suppressed ATF4 expression in glucose-deprived
conditions (Figure 3C), and the expression level of ATF4
protein was suppressed by AhR knockdown (Figure 3D).
These results indicate that ATF4 is included in the AhR
pathway and that AhR regulates ATF4 expression.
ATF4 but not Nrf2 mediates the induction of VEGF in
glucose deprivation
ATF4 was shown to induce the stress-induced expression
of VEGF [26]. In addition, ATF4 regulates VEGF expres-
sion in stress-induced angiogenesis, which interacts with
Nrf2 [27]. In HepG2 cells, the AhR pathway regulates the
stress-induced expression of Nrf2 [18]. Therefore, we raise
the following 3 hypotheses: A) Nrf2 induces VEGF expres-
sion by activating ATF4 expression; B) protein interactions
between Nrf2 and ATF4 induce VEGF expression; and C)
ATF4 activates VEGF expression independent of Nrf2 in
stress-induced angiogenesis (Figure 4).
Glucose deprivation-induced expression of VEGF was
examined using RNAi against ATF4 or Nrf2 at the mRNA
and protein levels (Figure 5). When HepG2 cells were
cultured under high glucose conditions, RNAi against
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Figure 1 The aryl hydrocarbon receptor (AhR) regulates vascular endothelial growth factor (VEGF) expression in glucose-deprived
conditions. A and D: mRNA expression of VEGF. A shows VEGF expression in glucose-deprived conditions, and D shows VEGF expression after
AhR knockdown. The VEGF mRNA levels were normalized by the β-actin mRNA level at each point (VEGF/β-actin). The values of VEGF/β-actin were
calculated relative to the expression level at 0 h (the time of medium exchange), which was set equal to 1. Bars indicate the standard deviation
of independent triplicate measurements. B and E: Western blot analyses using an antibody against VEGF. + and – indicate the presence and
absence, respectively, of glucose, control RNA, and AhR siRNA. C and F: Measurement of VEGF protein secretion to the media. “12 h” and “24 h” in
A, B and C indicate the time following transfer to high or no glucose medium. The RNA, protein and media samples in D, E and F were derived
from the HepG2 cells at 24 h after the medium exchange. * indicates that there is a significant difference (*: P < 0.05, **: P < 0.005).
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HepG2 cells were cultured under glucose-deprived con-
ditions, ATF4 knockdown suppressed VEGF expression
and secretion (Figure 5A,B and C). In contrast, Nrf2
knockdown did not affect VEGF expression at the mRNA
and protein levels and secretion of the VEGF protein
(Figure 5D,E and F). No appreciable change in ATF4 ex-
pression at the mRNA and protein levels occurred by
Nrf2 knockdown regardless of the glucose concentration
(Figure 6A and B).
Discussion
Lines of evidence suggest that AhR has important roles
in cancer pathogenesis, promotion, and malignancy
[28,29]. The activation of AhR by a typical agonist,2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), has been
shown to promote tumor formation in both liver and
skin [30]. TCDD-mediated liver tumor promotion in
multistage rat hepatocarcinogenesis has been studied
in detail because of its relevance in xenobiotic-induced
toxicity [31]. The expression of mutant AhR molecules
by mice and rats suggested that AhR plays a key role in
liver tumor promotion [32,33]. In addition, kynurenine
acts as an endogenous ligand of the human AhR, and the
TDO-AhR pathway is associated with the malignant
progression of human brain tumors [22]. Takeuchi et al.
and Rhoman et al. have shown that AhR has a role for
VEGF expression and angiogenesis in mouse [19,20].
Our results indicate that AhR regulates VEGF expression
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Figure 2 In silico analysis of VEGF regulation. A shows the candidates of direct regulators of VEGF expression that were extracted by Ingenuity
Pathway Analysis (IPA). B shows the pathway that was predicted by in silico analysis from AhR to VEGF expression. The direction of the lines
indicates the direction of the transcriptional regulation, and double-headed arrows indicate protein-protein interactions.
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in angiogenesis for tumor malignancy during carcino-
genesis [11]. Angiogenesis is well known as one of the
malignancy stages of cancer progression. Shweiki et al.
raised the possibility of inducing VEGF expression by
hypoxia and glucose deprivation in C6 cells, a clonal glial
cell line that is derived from a rat glial tumor [34]. Several
studies have demonstrated that glucose deprivation also
induces VEGF expression in different types of cells [35-37].
Yun et al. reported that glucose transporter 1 (GLUT1) and
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3
(PFKFB3) are important molecules for VEGF expression
under glucose deprived-conditions in DU145 cells, a human
prostate carcinoma cell line [37]. GLUT1 and PFKFB3 are
upregulated by hypoxia-inducible factor 1 (HIF1) [38,39].
Therefore, the VEGF pathway in glucose deprivation is
possibly linked to a hypoxia response pathway.
Cancer cells in poorly vascularized solid tumors are con-
stantly or intermittently exposed to glucose deprivation as
well as hypoxia [40]. Glucose deprivation activates the
unfolded protein response (UPR), a stress-signaling path-
way in tumor cells [41]. The UPR induces the expression of
the transcription factor ATF4 through PERK [42]. Glucose
deficiency or deprivation induces AhR translocation
into the nucleus, and the nuclear translocation of AhR
activates not only CYP1A1 and CYP1A2 expression [18]
but also ATF4 expression (Figure 3C). However, there are
no binding elements for AhR in the ATF4 transcriptional
regulatory domains, suggesting that other molecules medi-
ate AhR-ATF4 regulation. AhR forms a dimer with ARNT,
and the AhR-ARNTcomplex can bind to dioxin-responsiveelements to activate the transcription of various genes,
including CYP1A1 and 1A2 [43,44]. Tumor cells in the
microenvironment of a solid tumor are exposed to hypoxia
and/or nutrient deprivation. In the microenvironments
within a solid tumor, angiogenesis is triggered by the ex-
pression of various molecules including VEGF.
To understand the response of liver cancer cells to
nutrient deprivation, we propose 3 hypotheses for the
AhR-regulated pathway that induces VEGF in glucose-
deprived HepG2 cells: A) Nrf2 induces VEGF expression by
activating ATF4 expression; B) protein interactions between
Nrf2 and ATF4 induce VEGF expression; and C) ATF4 acti-
vates VEGF expression independent of Nrf2 (Figure 4).
Glucose deprivation-induced expression of VEGF was
examined at the mRNA and protein levels using RNAi
against ATF4 or Nrf2 (Figure 5). When HepG2 cells were
cultured under glucose deprivation, ATF4 knockdown
suppressed VEGF expression (Figure 5A). In contrast,
Nrf2 knockdown did not affect VEGF expression at the
mRNA and protein levels and secretion of the VEGF
protein (Figure 5D,E and F). No appreciable change in
ATF4 expression at the mRNA and protein levels resulted
from Nrf2 knockdown regardless of the glucose concentra-
tion (Figure 6). These results clearly indicated that ATF4
activated VEGF expression independent of Nrf2 in the
glucose-deprived HepG2 cells. We adopt hypothesis C
as illustrated in Figure 4.
Conclusions
The AhR is well known as a ligand-activated transcription
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Figure 3 AhR regulates activating transcription factor 4 (ATF4) expression in glucose-deprived conditions. A and C: mRNA expression of
ATF4. A shows ATF4 expression in glucose-deprived conditions, and C shows ATF4 expression after AhR knockdown. The ATF4 mRNA levels were
normalized by the β-actin mRNA level at each point (ATF4/β-actin). The ATF4/β-actin values were calculated relative to the expression level at 0 h
(A: the time of medium exchange, C: the time of knockdown), which was set equal to 1. Bars indicate the standard deviation of independent
triplicate measurements. * indicates that there is a significant difference (*: P < 0.05, **: P < 0.005). B and D: Western blot analyses using an
antibody against ATF4. + and – indicate presence and absence, respectively, of glucose, control RNA, and AhR siRNA. “12 h” and “24 h” in A and
B indicate the time following transfer to high or no glucose medium. The RNA and protein samples in C and D were derived from the HepG2
cells at 24 h after the medium exchange.
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Figure 4 Hypotheses of the relationships between AhR, nuclear factor erythroid-derived 2-related factor 2 (Nrf2), ATF4, and VEGF. The
hypotheses by IPA and past reports are raised (A, B and C, see the text for detail). Solid arrows indicate the activation of gene expression, and the
dotted line indicates a protein-protein interaction.













































































































































Figure 5 VEGF expression under glucose deprivation is induced by ATF4 but not Nrf2. A and D: mRNA expression of VEGF. A shows VEGF
expression after ATF4 knockdown, and D shows VEGF expression after Nrf2 knockdown. The VEGF mRNA levels were normalized by the β-actin
mRNA level at each point (VEGF/β-actin). The VEGF/β-actin values were calculated relative to the expression level at 0 h (the time of knockdown),
which was set equal to 1. Bars indicate the standard deviation of independent triplicate measurements. B and E: Western blot analyses using an
antibody against VEGF. + and – indicate the presence and absence, respectively, of glucose, control RNA, and ATF4 or Nrf2 siRNA. C and F:
Measurement of VEGF protein secretion to the media. All RNA, protein and media amples were derived from HepG2 cells at 24 h after
knockdown. * indicates that there is a significant difference (*: P < 0.05, **: P < 0.005).
Terashima et al. BMC Molecular Biology 2013, 14:27 Page 6 of 9
http://www.biomedcentral.com/1471-2199/14/27enzyme, CYP1 family genes. AhR translocates into the nu-
cleus following ligand binding and forms a complex with
ARNT. The AhR-ARNTcomplex binds to the XRE domain
to regulate target gene expression. In conclusion, the AhR
pathway, which involves ATF4, induces VEGF expression
in glucose-deprived human hepatoblastoma HepG2 cells.
AhR translocates into the nucleus in response glucose
deprivation in HepG2 and regulates gene expression.
However, there are no binding domains of AhR on the
transcriptional regulatory domain of ATF4. We expect
that there are some mediators between the AhR trans-
location into the nucleus and ATF4 expression. The
pathway from AhR to VEGF through ATF4 is a novel
pathway in glucose-deprived liver cancer cells, which is
related to the microenvironment within cancer tissue
that affects liver cancer malignancy.Methods
Cell culture
HepG2 (a human hepatocellular carcinoma, ATCC No.:
HB-8065) cells (1.0 × 105 cells/mL) were cultured in
Dulbecco’s modified Eagle’s medium (DMEM; high glucose:
4.5 g/L D-glucose; Gibco, Grand Island, NY, USA) supple-
mented with 10% fetal bovine serum (Hyclone, South Logan,
VT, USA, Lot FRC25965) and antibiotics (Gibco) at 37°C
in a CO2 incubator for 48 h as a pre-culture. After the
pre-culture, the media were changed to high or low glucose
(1.0 g/L D-glucose, Gibco) DMEM.
RNA extraction and quantitative reverse-transcription
polymerase chain reaction (qRT-PCR)
Total RNA was extracted from 3 independent HepG2

















































Figure 6 Nrf2 is not related to ATF4 expression. A shows ATF4 expression after Nrf2 knockdown. The ATF4 mRNA levels were normalized by the
β-actin mRNA level at each point (ATF4/β-actin). The ATF4/β-actin values were calculated relative to the expression level at 0 h (the time of knockdown),
which was set equal to 1. Bars indicate the standard deviation of independent triplicate measurements. * indicates that there is a significant difference
(*: P < 0.05, **: P < 0.005). B shows western blot analyses using an antibody against ATF4. + and – indicate the presence and absence, respectively, of
glucose, control RNA, and Nrf2 siRNA. All RNA or protein samples were derived from HepG2 cells at 24 h after knockdown.
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Total RNAs (1 μg) were used for cDNA synthesis with a
cDNA synthesis kit (Roche, Basel, Switzerland). Using
the first-strand cDNA, real-time PCR was performed
with a 7500 Real-Time PCR System (Applied Biosystems,
Tokyo, Japan).
RNA interference (RNAi) assay
The small interfering RNAs (siRNAs) against AhR, Nrf2,
and ATF4 and control siRNAs were supplied as Stealth
RNAs by Invitrogen (Carlsbad, CA, USA). The siRNA
sequences targeting human AhR, Nrf2, and ATF4 mRNAs
were designed. In addition, negative control siRNAs were
designed by scrambling the nucleotide sequence (scramble
sequence) of the siRNAs for human AhR, ATF4, and Nrf2.
The negative control siRNAs were designed without
homology to any other gene.
HepG2 cells were individually transfected with siRNAs
with lipofectamine (Invitrogen) for 48 h according to the
manufacturer’s instructions. All siRNA transfections were
performed by treating the cells with 10 nM siRNA.
The negative control group was treated with the same
concentration of the negative control siRNA. All alternative
control groups were treated with lipofectamine in the
absence of siRNA. The HepG2 cells were cultured for
48 h in high glucose conditions as a pre-culture with
siRNA or control siRNA. The suppression efficiency of
gene expressions show in Additional file 1: Figure S1.
Western blotting
HepG2 cells were lysed and separated into the cytosol
and nuclear fractions using the NER-PER Nuclear and
Cytoplasmic Extraction Reagent (Thermo Scientific,Rockford, IL, USA). The protein samples were subjected
to sodium dodecyl sulfate 10% polyacrylamide gel electro-
phoresis (10 μg protein) and transferred to a nitrocellulose
membrane. The blots were blocked with Chemiluminescent
Blocker (Millipore, Billerica, MA, USA) at room temperature
for 1 h and rinsed with tris-buffered saline containing 0.1%
Tween 20 (TBS-T). The blots were incubated overnight with
antibodies against VEGF (1:1000, SC-7269 Santa Cruz),
ATF4 (1:1000, SC-200, Santa Cruz), or β-actin (1:1000,
SC-130656, Santa Cruz) at 4°C, followed by washing
with TBS-T. The blot was subsequently incubated for 1.5 h
with a mouse-IgG (1:1000, ZYMED) secondary antibody in
Chemiluminescent Blocker at room temperature followed
by washes with TBS-T. After a chemiluminescent reac-
tion using Luminate Classico Western HRP Substrate
(Millipore), the bands were visualized with a LAS-3000
(Fujifilm, Tokyo, Japan).
Quantitation of VEGF protein secretion
Media were collected from 300,000 cells in 60 mm dishes
and centrifuged at 2000 r.p.m. for 10 min at 4°C. VEGF in
the medium was measured by using the Quantikine human
VEGF ELISA kit from R&D Systems (Minneapolis, MN,
USA) according to manufacturer’s instruction.
Analysis of the AhR-VEGF pathway by ingenuity
pathway analysis
We used an Ingenuity Pathway Analysis tool to search the
biological pathway from AhR to VEGF including the mole-
cules involved in the pathway. We used this tool to identify
candidate molecules that were glucose deprivation-induced
VEGF transcriptional regulators in conjunction with bio-
logical pathways that are activated by AhR.
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Additional file 1: Figure S1. Suppresseion eficiency of gene
expressions by RNAi. The graphs show AhR, ATF4 and Nrf2 expressions
under addition of siRNA for AhR, ATF4 and Nrf2 respectively. Each mRNA
levels were normalized by the β-actin mRNA level at each point
(AhR, ATF4 or Nrf2/β-actin). The values of AhR, ATF4 or Nrf2/β-actin were
calculated relative to the expression level at 0 h (the time of medium
exchange), which was set equal to 1. Bars indicate the standard deviation
of independent triplicate measurements. * indicates that there is a
significant difference (*: P < 0.05, **: P < 0.005).
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